Last reviewed · How we verify

Blue Earth Diagnostics — Portfolio Competitive Intelligence Brief

Blue Earth Diagnostics pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Flotufolastat (18F) Flotufolastat (18F) marketed Folate receptor-targeted PET imaging agent Folate receptor alpha (FR-α) Oncology
piflufolastat (18F) piflufolastat (18F) marketed PSMA-targeting PET imaging agent PSMA (prostate-specific membrane antigen) Oncology
rhPSMA-7.3 (18F) Injection rhPSMA-7.3 (18F) Injection phase 3 Radiopharmaceutical PSMA Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amsterdam UMC, location VUmc · 1 shared drug class
  2. Brigham and Women's Hospital · 1 shared drug class
  3. Genzyme, a Sanofi Company · 1 shared drug class
  4. Gustave Roussy, Cancer Campus, Grand Paris · 1 shared drug class
  5. HTA Co., Ltd. · 1 shared drug class
  6. IRCCS San Raffaele · 1 shared drug class
  7. ITEL Telecomunicazioni Srl · 1 shared drug class
  8. M.D. Anderson Cancer Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Blue Earth Diagnostics:

Cite this brief

Drug Landscape (2026). Blue Earth Diagnostics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/blue-earth-diagnostics. Accessed 2026-05-14.

Related